Biohaven Reports Second Quarter 2022 Financial Results and Reports Recent Business Developments
- Antitrust approvals have been granted by the relevant governing authorities, including the Federal Trade Commission (“FTC”), with respect to the previously announced Pfizer Inc. acquisition of Biohaven Pharmaceutical Holding Company Ltd.; preliminary proxy statement has been filed with the SEC
- NURTEC® ODT (rimegepant) TRx volumes grew 11% and net product revenue was $194 million, up sequentially 57%
- Anticipated closing of the merger agreement necessitates accounting of derivative losses in the amount of $1.57 per share resulting in a total second quarter reported net loss of $6.21 per share; non-GAAP adjusted net loss1 for the second quarter was $3.82 per share
- Featured 31 new and encore presentations, including three late-breakers and three oral presentations, spotlighting robust Nurtec ODT and zavegepant migraine data at the 64th annual scientific meeting of the American Headache Society; oral presentations included first of its kind study in migraine reporting on the safety and benefits of Nurtec ODT when used as preventive treatment and as-needed for acute treatment of migraine
- Zavegepant nasal spray New Drug Application (“NDA”) filing accepted by the U.S. Food and Drug Administration (“FDA”), with a Prescription Drug User Fee Act goal date set for first quarter of 2023
- Commenced enrollment in Phase 3 clinical trial assessing efficacy and safety of taldefgrobep alfa in patients with Spinal Muscular Atrophy
NEW HAVEN, Conn., Aug. 5, 2022 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders, today reported financial results for the second quarter ended June 30, 2022, and provided a review of recent accomplishments during and anticipated upcoming milestones.
Vlad Coric, M.D., Chairman and Chief Executive Officer of Biohaven, commented, “As expected, we observed a strong rebound in NURTEC ODT net revenue as first quarter seasonal dynamics abated. Net product revenue of $194 million for the quarter represented a 57% sequential increase compared to the first quarter and reflects strong product demand. In addition, the sales mix of our 2-pack (16-tablet count) of Nurtec ODT continued to ramp in the second quarter. Investments made in first quarter copay programs drove volume and net revenue growth, and the benefits of the only ‘all-in-one’ therapy to treat and prevent migraine continued to resonate with and improve the lives of patients living with migraine. And now, with the intranasal zavegepant NDA filing acceptance, we are closer to bringing a new, critical medication to market that offers migraine patients ultra-rapid relief in as early as 15 minutes, and addresses the needs of patients experiencing nausea or vomiting who need non-oral treatment options.”
Dr. Coric continued, “We are excited about the vast opportunities beyond CGRP and have made tremendous strides across our broader pipeline, starting with our program in focal epilepsy with what we believe is a best-in-class approach to Kv7 potassium channel activation. We are working hard to expedite enrollment in our Phase 1 trial and look forward to exploring its potential in other epilepsy types as well as in pain and affective disorders. Likewise, we recently dosed the first subject in our Phase 3 trial evaluating taldefgrobep alfa in subjects with Spinal Muscular Atrophy (SMA); we look forward to driving enrollment in this trial and exploring the potential of taldefgrobep alfa in additional indications. We also remain on track to report topline results from the verdiperstat arm of the platform trial in ALS, sponsored by the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital in the second half of the year. We are excited about the paradigm-shifting approaches we’re exploring across our expanding pipeline and will continue working determinedly to improve outcomes for patients living with neuroscience diseases.”
Second Quarter and Recent Business Highlights
- Q2 2022 net product revenue from sales of NURTEC ODT totaled $194 million, up sequentially 57% compared to Q1 2022 – NURTEC ODT has now achieved over 2,200,000 prescriptions, and over 79,000 unique prescribers through June 30, 2022, an increase of 11,500 prescribers from the first quarter, signaling continued traction across the prescribing community. The $194 million in net product revenues for the quarter represents a 109% increase over the second quarter of 2021 and a 57% increase from net product revenues over the first quarter of 2022. The increase of $70 million in net product revenues as compared to the first quarter of 2022 is due primarily to increased NURTEC ODT prescription sales volume and favorable pack mix per prescription. In addition, we continue to see improvements in patient affordability / copay support needs as patients satisfy annual deductible obligations. These are marginally offset by additional rebates during the second quarter of 2022 compared to the first quarter of 2022. The Company remains on track to meet full year 2022 net product sales guidance of $825 – $900 million.
- Antitrust approval granted for proposed acquisition by Pfizer; other closing conditions – As previously disclosed, Biohaven entered into an agreement and plan of merger with Pfizer, Inc. (“Pfizer”) on May 10, 2022, under which Pfizer will acquire Biohaven (the “Merger”). Under the terms of the agreement, Pfizer will acquire all outstanding shares of Biohaven not already owned by Pfizer for $148.50 per share in cash. Biohaven common shareholders, including Pfizer, will also receive 0.5 of a share of New Biohaven, a new publicly traded company that will retain Biohaven’s non-CGRP development stage pipeline compounds, per Biohaven common share. The boards of directors of both Biohaven and Pfizer have unanimously approved the transaction. Pfizer will pay transaction consideration totaling approximately $11.6 billion in cash. Pfizer will also make payments at closing to settle Biohaven’s third party debt and for the redemption of all outstanding shares of Biohaven’s redeemable preferred stock.
- Consummation of the Merger is conditioned upon, among other things, expiration or termination of any applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”). The applicable waiting period under the HSR Act expired at 11:59 p.m., ET, on June 27, 2022.
- In addition to antitrust approval in the United States, the Merger was cleared by the German Federal Cartel Office on June 13, 2022, and was cleared by the Austrian Federal Competition Authority on June 23, 2022. On June 24, 2022, in response to a briefing paper filed by Pfizer on May 20, 2022, the UK Competition and Markets Authority confirmed that no further information is required on the Merger.
- The Merger transaction is also subject to completion of the New Biohaven spin-off transaction and customary closing conditions, including the approval of Biohaven’s shareholders. The Company filed a preliminary proxy statement with the United States Securities and Exchange Commission (“SEC”) on July 1, 2022.
- U.S. FDA accepted Biohaven’s zavegepant NDA filing for the acute treatment of migraine in adults – In May, the Company announced that the FDA filed and accepted for review the Company’s recently submitted NDA for zavegepant, the only small molecule calcitonin gene-related peptide (“CGRP”) receptor antagonist in an intranasal formulation, for the acute treatment of migraine in adults. The Prescription Drug User Fee Act (“PDUFA”) goal date for completion of the FDA review of the NDA is set for the first quarter of 2023. The Company had announced the achievement of positive results in the pivotal trial of zavegepant for the acute treatment of migraine in adults in December, 2021.
- Commenced enrollment in Phase 3 Spinal Muscular Atrophy (“SMA”) study – In July, the Company commenced enrollment in a Phase 3 clinical trial assessing the efficacy and safety of taldefgrobep alfa in Spinal Muscular Atrophy (SMA). Taldefgrobep targets myostatin, a natural protein that limits skeletal muscle growth, through two mechanisms: lowering myostatin directly and blocking key downstream signaling mechanisms. The Company expects to enroll approximately 180 patients in this randomized, double-blind, placebo-controlled global trial.
- Global Coalition for Adaptive Research (“GCAR”) commenced enrollment in Glioblastoma Adaptive Global Innovative Learning Environment (“GBM Agile”) Phase 2-3 adaptive platform trial for patients with glioblastoma – In July, GCAR announced the activation of Biohaven’s troriluzole and Vigeo Therapeutics’ VT1021 in GBM AGILE, a patient-centered, adaptive platform trial for registration that tests multiple therapies for patients with newly-diagnosed and recurrent glioblastoma (“GBM”). GBM AGILE is an international, innovative platform trial designed to more rapidly identify and confirm effective therapies for patients with glioblastoma through response adaptive randomization. The new interventions are opening first at Henry Ford Health Cancer in Detroit under Henry Ford site Principal Investigator Dr. Tom Mikkelsen and will subsequently open at more than 40 trial sites across the United States with additional global sites to follow.
- Phase 3 clinical trial of troriluzole did not reach statistical significance in overall SCA population – In May, the Company announced top-line results from a Phase 3 clinical trial evaluating the efficacy and safety of its investigational therapy, troriluzole, in patients with spinocerebellar ataxia (SCA). The primary endpoint, change from baseline to Week 48 on the modified functional Scale for the Assessment and Rating of Ataxia (f-SARA), did not reach statistical significance in the overall SCA population as there was less than expected disease progression over the course of the study. However, post hoc analysis of efficacy measures by genotype suggested a treatment effect in patients with the SCA Type 3 (SCA3) genotype, which represents the most common form of SCA and accounted for 41 percent of the study population. In the SCA3 subgroup, troriluzole showed a numerical treatment benefit on the change in f-SARA score from baseline to Week 48 compared to placebo. Given the debilitating nature of the disease and lack of approved therapies, the Company intends to share the SCA3 genotype data with regulators and work with the FDA to address a path forward for troriluzole in SCA.
- Presented new Nurtec ODT, zavegepant, and migraine health economics and outcomes research (HEOR) data at the American Headache Society Annual Scientific Meeting – In June, the Company presented 31 new and encore presentations, including three late-breakers and three oral presentations, at the 64th annual scientific meeting of the American Headache Society. Key updates:
- The Company presented full Phase 3 results for zavegepant nasal spray as an acute treatment of migraine as well as data from a 52-week open label extension study of Nurtec® ODT (rimegepant) evaluating every other day preventive treatment of migraine plus as an as-needed acute treatment, and estimated reductions in monthly migraine days (MMDs) with rimegepant acute treatment.
- Late-breaking submissions highlighted new data about patterns of medication utilization and migraine frequency for adults using Nurtec ODT as a preventive and acute treatment, results from a Phase 1 trial of Nurtec ODT in healthy Chinese adults, and outcomes of a Phase 3 study of Nurtec ODT conducted in China and Korea as an acute treatment of migraine.
- Several HEOR posters notably highlighted (1) reductions in the prevalence of medication overuse headache following Nurtec ODT initiation, (2) reduced mean monthly quantity of dispensed Nurtec ODT which is potentially reflective of MMD reductions, (3) patient survey studies that illustrate preference for ODT oral formulations versus injectable or IV treatments in prevention, (4) improvements in health-related quality of life with long-term Nurtec ODT treatment, (5) the high interictal burden of migraine, and (6) patient reported attenuation of effect with biologic treatment in prevention.
Biohaven is continuing to support the commercialization of NURTEC ODT for the acute and preventive treatment of migraine, as well as develop its product candidates through clinical and preclinical programs in a number of common and rare disorders. The Company expects to reach significant pipeline milestones across its platforms in the coming quarters.
Biohaven expects to:
- Consummate the acquisition by Pfizer by early 2023, subject to the completion of the new Biohaven spin-off transaction and other customary closing conditions.
- Advance Phase 1 study of BHV-7000 (Kv7) in focal epilepsy.
- Continue to advance the commercialization of NURTEC ODT (rimegepant) for the acute and preventive treatment of migraine.
- Continue to advance the zavegepant (intranasal spray) program towards commercialization for the acute treatment of migraine.
- Submit an NDA for the acute treatment of migraine in China in the second half of 2022.
- Report topline of verdiperstat in ALS in the second half of 2022.
- Complete enrollment in Phase 3 study of troriluzole in Obsessive-Compulsive Disorder in 2023.
Cash, cash equivalents, and marketable securities as of June 30, 2022, were $553.5 million, excluding $0.8 million of restricted cash, compared to $364.6 million as of December 31, 2021. On January 4, 2022, we received $500.0 million in upfront proceeds from Pfizer relating to our strategic collaboration arrangement, consisting of $150.0 million cash and $350.0 million in proceeds from the purchase of Biohaven common shares at a 25% market premium. In addition, during the second quarter of 2022 we drew $125.0 million in non-dilutive committed capital from our credit facility with Sixth Street.
Second Quarter 2022 Financial Highlights
Product Revenue, Net: Net product revenue was $194.0 million for the three months ended June 30, 2022, compared to $92.9 million for the three months ended June 30, 2021. The increase of $101.0 million in net product revenue was primarily due to increased NURTEC ODT sales volume as well as an increase in average pills per prescription during the three months ended June 30, 2022, compared to the three months ended June 30, 2021. The increase in the second quarter of 2022 compared to the second quarter of 2021 was also benefited from improved patient affordability support, partially offset by additional rebate related sales allowances.
Collaboration and Other Revenue: Collaboration and other revenue was $21.1 million for the three months ended June 30, 2022. No collaboration and other revenue was recognized for the three months ended June 30, 2021. The collaboration and other revenue recognized during the three months ended June 30, 2022 was primarily due to $20.0 million of variable consideration recognized as part of our collaboration arrangement with Pfizer.
Research and Development (“R&D”) Expenses: R&D expenses, including non-cash share-based compensation costs, were $218.5 million for the three months ended June 30, 2022, compared to $77.4 million for the three months ended June 30, 2021. The increase of $141.1 million was primarily due to the acquisition of our Kv7 Platform from Knopp Biosciences LLC in April 2022 for $93.7 million and a $25.0 million development milestone related to BHV-7000, increased program expenses for rimegepant, and increased personnel costs. Non-cash share-based compensation expense was $16.6 million for the three months ended June 30, 2022, an increase of $7.4 million as compared to the same period in 2021.
Selling, General and Administrative (“SG&A”) Expenses: SG&A expenses, including non-cash share-based compensation costs, were $250.5 million for the three months ended June 30, 2022, compared to $170.1 million for the three months ended June 30, 2021. The increase of $80.4 million was primarily due to increases in spending to support increased commercial sales of NURTEC ODT, including the launch of NURTEC ODT for the preventative treatment of migraine which was approved by the FDA in May of 2021. Additionally, approximately $9.6 million of the increased SG&A expense related to fees incurred in connection with the Pfizer Merger, including increased legal and accounting costs. Less than half of the SG&A expense was for commercial organization personnel costs, excluding non-cash share-based compensation expense. Non-cash share-based compensation expense was $23.6 million for the three months ended June 30, 2022, an increase of $7.3 million as compared to the same period in 2021.
Other Expense, Net: Other expense, net was $152.2 million for the three months ended June 30, 2022, compared to $34.9 million for the three months ended June 30, 2021. The increase of $117.3 million in net expense was primarily due to a $109.7 million change in fair value of derivative liabilities, as well as $9.3 million of increased interest expense as a result of additional borrowings under our debt facility with Sixth Street Specialty Lending, Inc. (“Sixth Street”). The change in fair value of derivative liabilities was a result of derivative liabilities recorded in connection with change of control provisions associated with the pending acquisition of Biohaven by Pfizer for our series A and B preferred shares and term loans with Sixth Street.
Net Loss: Biohaven reported a net loss attributable to common shareholders for the three months ended June 30, 2022, of $441.4 million, or $6.21 per share, compared to $210.6 million, or $3.23 per share for the same period in 2021. Anticipated closing of the merger agreement necessitates accounting of derivative losses in the amount of $1.57 per share resulting in a total second quarter reported net loss of $6.21 per share. Non-GAAP adjusted net loss for the three months ended June 30, 2022 was $271.4 million, or $3.82 per share, compared to $170.9 million, or $2.62 per share for the same period in 2021. These non-GAAP adjusted net loss and non-GAAP adjusted net loss per share measures, more fully described below under “Non-GAAP Financial Measures,” exclude non-cash share-based compensation charges, non-cash interest expense related to the accounting for mandatorily redeemable preferred shares and liability related to sale of future royalties, changes in the fair value of derivatives and gains or losses from equity method investment.